Hassan B. Alkhateeb

2.5k total citations
148 papers, 743 citations indexed

About

Hassan B. Alkhateeb is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Hassan B. Alkhateeb has authored 148 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hematology, 58 papers in Genetics and 26 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Hassan B. Alkhateeb's work include Acute Myeloid Leukemia Research (84 papers), Chronic Myeloid Leukemia Treatments (44 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers). Hassan B. Alkhateeb is often cited by papers focused on Acute Myeloid Leukemia Research (84 papers), Chronic Myeloid Leukemia Treatments (44 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers). Hassan B. Alkhateeb collaborates with scholars based in United States, Saudi Arabia and Canada. Hassan B. Alkhateeb's co-authors include Mrinal M. Patnaik, Mark R. Litzow, William J. Hogan, Aref Al‐Kali, Naseema Gangat, Ayalew Tefferi, Mithun Vinod Shah, Kebede H. Begna, Animesh Pardanani and Kristen McCullough and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hassan B. Alkhateeb

120 papers receiving 740 citations

Peers

Hassan B. Alkhateeb
Gladstone Airewele United States
Ana Vidović Serbia
Raquel de Paz Spain
Oren Pasvolsky Israel
Hyery Kim South Korea
Andrew C. Dietz United States
Stephanie Farnia United States
Gülersu İrken Türkiye
Maija Itälä‐Remes Finland
Alaa Elhaddad Egypt
Gladstone Airewele United States
Hassan B. Alkhateeb
Citations per year, relative to Hassan B. Alkhateeb Hassan B. Alkhateeb (= 1×) peers Gladstone Airewele

Countries citing papers authored by Hassan B. Alkhateeb

Since Specialization
Citations

This map shows the geographic impact of Hassan B. Alkhateeb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hassan B. Alkhateeb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hassan B. Alkhateeb more than expected).

Fields of papers citing papers by Hassan B. Alkhateeb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hassan B. Alkhateeb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hassan B. Alkhateeb. The network helps show where Hassan B. Alkhateeb may publish in the future.

Co-authorship network of co-authors of Hassan B. Alkhateeb

This figure shows the co-authorship network connecting the top 25 collaborators of Hassan B. Alkhateeb. A scholar is included among the top collaborators of Hassan B. Alkhateeb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hassan B. Alkhateeb. Hassan B. Alkhateeb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mohty, Razan, Ahmad Halwani, Talha Badar, et al.. (2025). Malignancies after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy. 31(11). 863–873.
2.
Baranwal, Anmol, Mehrdad Hefazi, Abhishek A. Mangaonkar, et al.. (2024). Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis. Transplantation and Cellular Therapy. 30(2). S264–S265.
3.
Badar, Talha, James M. Foran, Mohamed A. Kharfan‐Dabaja, et al.. (2024). Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series. Blood. 144(Supplement 1). 1823–1823. 1 indexed citations
4.
Bansal, Radhika, Hassan B. Alkhateeb, Stephen M. Ansell, et al.. (2024). Metformin and cytokine release syndrome after immune effector cell therapy.. Journal of Clinical Oncology. 42(16_suppl). e14535–e14535.
5.
Badar, Talha, Keith L. Knutson, James M. Foran, et al.. (2024). T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia. Blood Advances. 9(2). 239–243. 6 indexed citations
6.
Palmisiano, Neil, Ju‐Whei Lee, David F. Claxton, et al.. (2024). A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. SHILAP Revista de lepidopterología. 5(5). 951–956. 1 indexed citations
7.
Ji, Yuan, et al.. (2023). Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations. Current Hematologic Malignancy Reports. 18(5). 121–129. 3 indexed citations
8.
Badar, Talha, James M. Foran, David S. Viswanatha, et al.. (2023). Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms. Haematologica. 108(11). 3033–3043. 10 indexed citations
9.
McCullough, Kristen, Aref Al‐Kali, Hassan B. Alkhateeb, et al.. (2023). Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent. Blood. 142(Supplement 1). 2853–2853. 1 indexed citations
10.
Badar, Talha, Hassan B. Alkhateeb, Mahmoud Aljurf, & Mohamed A. Kharfan‐Dabaja. (2023). Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era. Current Research in Translational Medicine. 71(2). 103392–103392. 1 indexed citations
11.
Badar, Talha, James M. Foran, Aref Al‐Kali, et al.. (2023). U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer Journal. 13(1). 149–149. 7 indexed citations
12.
Baranwal, Anmol, Rakchha Chhetri, Chung Hoow Kok, et al.. (2022). Factors Predicting Survival Following Allogeneic Stem Cell Transplant in Patients with Therapy-Related Myeloid Neoplasms. Transplantation and Cellular Therapy. 28(3). S137–S138. 2 indexed citations
13.
Baranwal, Anmol, Aref Al‐Kali, James M. Foran, et al.. (2022). Allogeneic Stem Cell Transplant Outcomes in Patients with DDX41 Mutated Myeloid Malignancies. Transplantation and Cellular Therapy. 28(3). S126–S127. 1 indexed citations
14.
Shah, Mithun Vinod, Rakchha Chhetri, Chung Hoow Kok, et al.. (2022). Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms. American Journal of Hematology. 97(8). 1013–1022. 8 indexed citations
15.
Begna, Kebede H., Naseema Gangat, Hassan B. Alkhateeb, et al.. (2022). European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer Journal. 12(1). 7–7. 4 indexed citations
16.
Tefferi, Ayalew, Naseema Gangat, Aref Al‐Kali, et al.. (2022). A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. American Journal of Hematology. 97(9). 1127–1134. 6 indexed citations
17.
Litzow, Mark R., et al.. (2021). Clinical Outcomes of Post Allogeneic Stem Cell Transplant Splenectomy in Primary Myelofibrosis for Delayed Engraftment. Transplantation and Cellular Therapy. 27(3). S428–S429.
18.
Rahman, Zaid Abdel, Ricardo Parrondo, Michael G. Heckman, et al.. (2021). Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 196(4). 963–968. 7 indexed citations
19.
Nadiminti, Kalyan, Mehrdad Hefazi, Yogesh Jethava, et al.. (2021). A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal. 11(11). 183–183. 2 indexed citations
20.
Morsia, Erika, Kristen McCullough, Joselle Cook, et al.. (2020). Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. American Journal of Hematology. 95(12). 1511–1521. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gladstone Airewele Breakdown of academic impact, for papers by Ana Vidović Breakdown of academic impact, for papers by Raquel de Paz Breakdown of academic impact, for papers by Oren Pasvolsky Breakdown of academic impact, for papers by Hyery Kim Breakdown of academic impact, for papers by Andrew C. Dietz Breakdown of academic impact, for papers by Stephanie Farnia Breakdown of academic impact, for papers by Gülersu İrken Breakdown of academic impact, for papers by Maija Itälä‐Remes Breakdown of academic impact, for papers by Alaa Elhaddad
Rankless by CCL
2026